• By ICR Secretariat
  • Posted Thursday, April 14, 2022

UK patients granted early access for radioligand therapy in advanced prostate cancer

https://www.pharmatimes.com/news/uk_patients_granted_early_access_for_radioligand_therapy_in_advanced_prostate_cancer_1389919

Advanced Accelerator Applications (AAA), a Novartis company, has announced that eligible patients in the UK have been granted early access for radioligand therapy in advanced prostate cancer, a disease which causes over 11,500 deaths in the UK alone each year.